Evaluation of the tolerance and distribution of intravenously applied ferrofluid particles of 250 and 500nm size in an animal model

Journal of Drug Targeting

Volumn 17, Issue 3, 2009, Pages 194-199

  Wiegand, Susanne ^a   Heinen, Thomas ^a   Ramaswamy, Annette ^a   Sesterhenn, Andreas M ^a   Bergemann, Christian ^b   Werner, Jochen A ^a   Lbbe, Andreas S ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b Philipps University Marburg ^*

Author keywords

Cancer targeting; Drug targeting; Ferrofluid; Magnetic carriers; Nanoparticles

Indexed keywords

FERROFLUID; NANOPARTICLE; UNCLASSIFIED DRUG; MAGNETITE; METAL NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERANCE; EMBOLISM; HISTOPATHOLOGY; MALE; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RABBIT; SEROLOGY; THROMBOSIS; ANIMAL; DRUG DELIVERY SYSTEM; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; TISSUE DISTRIBUTION;

ANIMALS; DRUG DELIVERY SYSTEMS; FERROSOFERRIC OXIDE; INJECTIONS, INTRAVENOUS; MALE; METAL NANOPARTICLES; MODELS, ANIMAL; PARTICLE SIZE; RABBITS; TISSUE DISTRIBUTION;

EID: 70149110440     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.1080/10611860802582467     Document Type: Article

References (10)

1. Alexiou C, Arnold W, Klein RJ, Parak FG, Hulin P, Bergemann C, Erhardt W, Wagenpfeil S, Lübbe AS. (2000). Locoregional cancer treatment with magnetic drug targeting. Cancer Res 60: 6641-6648.
2. Alexiou C, Jurgons R, Schmid RJ, Bergemann C, Henke J, Erhardt W, Huenges E, Parak F. (2003). Magnetic drug targeting-biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment. J Drug Target 11:139-149.
3. Audus KL, Borchardt RT. (1991). Transport of macromolecules across the capillary endothelium. In: Juliano RL. Targeted drug delivery. Berlin Heidelberg: Springer-Verlag. p. 43-70.
4. Bacon BR, Stark DD, Park Ch, Saini S, Groman EV, Hahn PF, Compton CC, Ferrucci JT. (1987). Ferrite particles: a new magnetic resonance imaging contrast agent. Lack of acute or chronic hepatotoxicity after intravenous administration. J Lab Clin Med 110: 164-171.
5. Lübbe AS, Bergemann C. (1998). Magnetically controlled drug targeting. Cancer J 11:104-105.
6. Lübbe AS, Bergemann C, Huhnt W, Fricke T, Riess H, Brock JW, Huhn D. (1996a). Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res 56:4694-4701.
7. Lübbe AS, Bergemann C, Riess H, Schriever F, Reichhardt P, Possinger K, Matthias M, Dörken B, Herrmann F, Gürtler R, Hohenberger P, Haas N, Sohr R, Sander B, Lemke AJ, Ohlendorf D, Huhnt W, Huhn D. (1996B). Clinical experiences with magnetic drug targeting: a phase I study with 49-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res 56:4686-4693.
8. Lübbe AS, Bergemann C, Brock J, McClure DG. (1999). Physiological aspects in magnetic drug-targeting. J Magn Magn Mater 194:149-155.
9. Van Hecke P, Marchal G, Decrop E, Baert AL. (1989). Experimental study of the pharmacokinetics and dose response of ferrite particles used as contrast agent in MRI of the normal liver of the rabbit. Invest Radiol 24:397-399.
10. Weisleder R, Stark DD, Engelstad BL, Bacon BR, Compton CC, White DL, Jakobs P, Lewis J. (1989). Superparamagnetic iron oxide: pharmacokinetics and toxicity. AJR 152:167-173.